Department of Pediatric Gastroenterology, Hepatology and Nutrition, Rehabilitation Center for Intestinal Failure and Home Parenteral Nutrition, Necker-Enfants Malades Hospital, Paris, France.
University Paris Descartes, Paris, France.
JPEN J Parenter Enteral Nutr. 2018 Aug;42(6):1017-1025. doi: 10.1002/jpen.1043. Epub 2018 Jan 31.
Catheter-related bloodstream infections (CRBSIs) remain a major issue in patients who are receiving home parenteral nutrition (HPN). The aim of this interventional study was to assess the impact of a new strategy using taurolidine-citrate (T-C) prophylactic locks on the CRBSI rate in children with intestinal failure who are receiving HPN.
The rate of CRBSIs was monitored every calendar year in a prospective cohort of 195 children with intestinal failure. T-C locks were initiated from October 2011 in children with recurring CRBSIs (≥2 episodes per year).
In the whole cohort, the median annual CRBSI rate per 1000 catheter days decreased significantly from 2.07 in 2008 to 2010 to 1.23 in 2012 to 2014 (P < .05). T-C locks were used in 40 patients. No adverse events were reported. In taurolidine-treated patients, the CRBSI rate per 1000 catheter days decreased from 4.16 to 0.25 (P < .0001). The cumulative percentage of patients free of CRBSI at 18 months was 92% (95% confidence interval [CI]: 71-98) on T-C lock vs 61% (95% CI: 49-72) in controls (P = .01). In multivariate analysis, factors associated with CRBSI were immune deficiency (adjusted hazard ratio 3.49; 95% CI: 1.01-12.17) and the young age of the parents (adjusted hazard ratio 4.79, 95% CI: 2.16-10.62), whereas T-C locks were protective (adjusted hazard ratio 0.22, 95% CI: 0.06-0.74).
This study confirms the efficacy of T-C catheter locks in decreasing the incidence of CRBSIs in children with intestinal failure who are receiving HPN.
在接受家庭肠外营养(HPN)的患者中,导管相关血流感染(CRBSI)仍然是一个主要问题。本干预研究的目的是评估在接受 HPN 的肠衰竭儿童中使用 taurolidine-citrate(T-C)预防性锁预防 CRBSI 的新策略的效果。
在一个前瞻性队列的 195 例肠衰竭患儿中,每一年度监测 CRBSI 的发生率。从 2011 年 10 月起,对反复发生 CRBSI(每年≥2 次)的患儿开始使用 T-C 锁。
在整个队列中,每千导管日的中位年度 CRBSI 发生率从 2008 年至 2010 年的 2.07 显著降低至 2012 年至 2014 年的 1.23(P<.05)。T-C 锁用于 40 例患儿。未报告不良事件。在 taurolidine 治疗的患儿中,每千导管日的 CRBSI 发生率从 4.16 降至 0.25(P<.0001)。在 T-C 锁组,18 个月时无 CRBSI 的患者累积百分比为 92%(95%CI:71-98),而对照组为 61%(95%CI:49-72)(P=.01)。在多变量分析中,与 CRBSI 相关的因素是免疫缺陷(调整后的危险比 3.49;95%CI:1.01-12.17)和父母年龄较小(调整后的危险比 4.79,95%CI:2.16-10.62),而 T-C 锁具有保护作用(调整后的危险比 0.22,95%CI:0.06-0.74)。
本研究证实了 T-C 导管锁在降低接受 HPN 的肠衰竭患儿 CRBSI 发生率方面的有效性。